CHURCHILL MANAGEMENT Corp Acquires 44,218 Shares of Pfizer Inc. $PFE

CHURCHILL MANAGEMENT Corp raised its holdings in Pfizer Inc. (NYSE:PFE) by 13.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 371,083 shares of the biopharmaceutical company’s stock after acquiring an additional 44,218 shares during the quarter. CHURCHILL MANAGEMENT Corp’s holdings in Pfizer were worth $8,995,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Bessemer Group Inc. lifted its stake in shares of Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after purchasing an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK raised its stake in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after buying an additional 17,032 shares during the last quarter. Westbourne Investments Inc. purchased a new stake in Pfizer in the first quarter valued at about $2,411,000. Bourne Lent Asset Management Inc. raised its stake in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after buying an additional 18,200 shares during the last quarter. Finally, Strs Ohio purchased a new stake in Pfizer in the first quarter valued at about $49,968,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Morgan Stanley increased their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Bank of America increased their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.29.

Pfizer Stock Up 6.8%

Shares of PFE stock opened at $27.21 on Thursday. The stock’s 50-day simple moving average is $24.59 and its 200-day simple moving average is $24.14. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $154.68 billion, a PE ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.